Why Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 5.79%
As of Tuesday, October 06, Telomir Pharmaceuticals, Inc.’s TELO share price has surged by 5.79%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Stock Evaluator: Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. TELO
$1.09
-0.01
-0.91%
October 13, 2026 4:00:00 PM
EST
Volume: 53,828
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson’s disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer’s disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Commentary & Analysis
Why Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 6.78%
As of Monday, October 05, Telomir Pharmaceuticals, Inc.’s TELO share price has surged by 6.78%, which has investors questioning if this is right time to sell.Michael Rose
Why Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 6.19%
As of Thursday, September 17, Telomir Pharmaceuticals, Inc.’s TELO share price has surged by 6.19%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 5.17%
As of Tuesday, September 08, Telomir Pharmaceuticals, Inc.’s TELO share price has surged by 5.17%, which has investors questioning if this is right time to sell.Michael Rose
Why Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 6.19%
As of Monday, August 24, Telomir Pharmaceuticals, Inc.’s TELO share price has surged by 6.19%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | TELO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $81.0 | $511.9 | 20% |
|
| Shares Out (Mil) | 60.8 | 42.8 | 52% |
|
| Institutional Ownership | 17.4% | 82.8% | 9% |
|
| Float (Mil) | 42.0 | 44.4 | 43% |
|
| Beta | -0.24 | 0.70 | 3% |
|
| Avg Daily Volume (000s) | 199 | 372 | 44% |
|
| Price Change (52-week) |
(43.0%) | 59.4% | 23% |
|
| Growth | TELO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TELO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($6) | ($11) | 33% |
|
| EPS (TTM) | ($1.288) | ($0.700) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | ($7) | 25% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $73 | $494 | 19% |
|
| Valuation | TELO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 15.71 | 2.24 | 94% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TELO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (189.7%) | (22.2%) | 2% |
|
| ROE | (213.1%) | (21.4%) | 4% |
|
| Liabilities to Assets | 6.2% | 32.8% | 3% |
|
| F-Score | 3 | 3 | 18% |
|
Telomir Pharmaceuticals, Inc. did not pass any screens on 10/12/2026.
